Normand can talk to the industry level.
In terms of investment in Canada and actually products produced, we at Merck Frosst have a very large therapeutic research centre in Kirkland, with about 300 world-class citizens. We've developed about half a dozen products there over the years: Blocadren, Timoptic, Flexeril, Singulair, Arcoxia, and now Laropiprant.
I think there are some good examples of Canadian developments in Canada. As well, we have been investing about $120 million a year in Canadian R and D. That's more than $2 billion over the past 15 years. We put that research facility in as a result of the government's announcement to enhance patent protection.
So I think there are some good examples of where there has been some direct benefit from that patent protection.